<DOC>
	<DOC>NCT00194064</DOC>
	<brief_summary>Inpatient Study Evaluating the Safety and Efficacy of Open-Label Olanzapine Monotherapy in Treatment Refractory Bipolar Mania: This study recruits adult subjects who are diagnosed with Bipolar I Disorder and presently experiencing an episode of mania. Patients must be willing to spend initial 7 days in the hospital to observe response to medication. Patients must be refractory (intolerant or non-responsive) to treatment with lithium and valproate or carbamazepine. Patients receive study-related care at no cost. This study is sponsored by Eli Lilly and Company.</brief_summary>
	<brief_title>Pilot Study Evaluating the Safety and Efficacy of Open-Label Olanzapine</brief_title>
	<detailed_description />
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>The subject satisfied Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSMIV) criteria for a primary diagnosis of Bipolar Disorder, most recently manic The patient is willing to be hospitalized on an inpatient psychiatric unit for a minimum of seven (7) days. Subject has been treated with lithium in the past. Subject has been treated with divalproex or carbamazepine in the past. Subject has been treated with Haldol or haloperidol in the past. Subjects lacks the capacity to provide informed consent Subject is a serious suicide risk or has medically unstable conditions as judged by the investigators Subject has been dependent on a drug (other than nicotine or caffeine) in the last three (3) months.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>